Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

9,611JPY
10:29pm EDT
Change (% chg)

¥137 (+1.45%)
Prev Close
¥9,474
Open
¥9,629
Day's High
¥9,726
Day's Low
¥9,606
Volume
342,800
Avg. Vol
1,409,868
52-wk High
¥11,490
52-wk Low
¥5,402

Chart for

About

Eisai Co., Ltd. is engaged in the research and development, manufacture, sale and import and export of pharmaceuticals. The Company's business segments include pharmaceutical segment and other segment. The pharmaceutical segment is engaged in the research, develop, manufacture and sale of pharmaceuticals for medical use, generic... (more)

Overall

Beta: 0.68
Market Cap(Mil.): ¥2,894,494.00
Shares Outstanding(Mil.): 296.57
Dividend: 70.00
Yield (%): 1.56

Financials

  4523.T Industry Sector
P/E (TTM): 50.59 29.16 32.45
EPS (TTM): 189.67 -- --
ROI: 7.58 13.25 12.93
ROE: 9.28 15.25 15.12

Eisai shares fall 18 pct after release of Alzheimer drug test details

TOKYO, July 26 Shares of Japanese drugmaker Eisai fell more than 18 percent on Thursday after the company and its partner Biogen Inc presented the details of their experimental drug on Alzheimer's disease. (Reporting by Hideyuki Sano; Editing by Stephen Coates)

Jul 25 2018

Biogen/Eisai Alzheimer's drug cut cognitive decline by 30 pct -study

CHICAGO, July 25 Biogen Inc and partner Eisai Co Ltd said patients with early-stage Alzheimer's disease treated with their experimental drug BAN2401 experienced 30 percent less cognitive decline than patients who got a placebo in a highly anticipated midstage trial.

Jul 25 2018

Biogen's Alzheimer's drug succeeds in mid-stage trial

July 5 Japanese drugmaker Eisai Co and Biogen Inc said on Thursday that the final analysis of a mid-stage trial of their Alzheimer's drug showed positive results for patients who received the highest dose.

Jul 05 2018

BRIEF-Nichi-Iko Pharmaceutical says business and capital alliance with Eisai

* Says it forms business and capital alliance with Eisai Co Ltd

Mar 28 2018

BRIEF-Anticancer Agent Lenvima Approved For Additional Indication Of Unresectable Hepatocellular Carcinoma In Japan

* ANTICANCER AGENT LENVIMA® (LENVATINIB MESYLATE) APPROVED FOR ADDITIONAL INDICATION OF UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) IN JAPAN, FIRST APPROVAL WORLDWIDE FOR LENVIMA FOR HCC

Mar 23 2018

Eisai clinches Merck deal to develop and sell cancer drug, shares soar

(This March 8 story has been corrected to show in the 7th paragraph that Merck will pay, not receive, R&D reimbursement)

Mar 09 2018

CORRECTED-UPDATE 3-Eisai clinches Merck deal to develop and sell cancer drug, shares soar

* Eisai's drug Lenvima already approved in dozens of countries

Mar 09 2018

BRIEF-Eisai Co, Merck Announce Oncology Collaboration For Lenvima

* EISAI CO., LTD. AND MERCK ENTER GLOBAL STRATEGIC ONCOLOGY COLLABORATION FOR LENVIMA® (LENVATINIB MESYLATE)

Mar 07 2018

Merck, Eisai sign deal to further develop, sell Eisai cancer drug

March 7 Merck & Co and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in many countries for two uses.

Mar 07 2018

Earnings vs. Estimates